Immunohistochemical Expression of AMACR Tumor Marker Among Colorectal tumors

Abstract

This is a hospital based descriptive retrospective study conducted at Soba university hospital (Khartoum state) and Sudan University of Sciences and Technology, College of Medical Laboratory Sciences during the period from may to September 2013, aimed to detect Alpha-methylacyl-CoA recemase (AMACR) in colorectal tumors patients using immunohistochemistry. Thirty five paraffin block samples were collected from patients samples previously diagnosed as colorectal tumor ( 27 of were whom malignant colorectal samples and 8 of whom benign colorectal samples) using simple random collection method. The paraffin blocks were cut by rotary microtome, and then stained by immunohistochemical method using modified new indirect Dako technique for detection of AMACR. The data obtained was analyzed using SPSS program version 15.0. The age of the patients ranged between 19 to 78 years old with mean age of 52 year. The study revealed that most patients were older than 40 years representing 19 (54.3%) and the remaining 6 (17.1%) were younger than 40 years. Out of thirty five patients, the majority of patients were males representing 19 (54.3%) and the remaining 16 (45.7%) were females. AMACR expression showed positive among malignant colorectal tumors in 14 (40.0%) patients and negative expression in 13 (37.1%) patients, while all benign colorectal tumors gave negative expression. AMACR expression gave positive expression well differentiated tumor (3.7%) patient and negative expression in 3 (11.1%) patients, moderately differentiated tumor positive expression in 13 (48.1%) patients and negative expression in 8 (29.6%) patients while all poor differentiated tumor negative expression 2 (7.4%). The study concluded that the AMACR expression associated with malignant colorectal tumors, with no association with the grade of cancer.